SPY411.49+2.97 0.73%
DIA337.86+2.73 0.81%
IXIC13,900.19+70.88 0.51%

BRIEF-Translate Bio Announces Results From Second Interim Data Analysis From Ongoing Phase 1/2 Clinical Trial Of MRT5005 In Patients With Cystic Fibrosis

· 03/17/2021 16:13
BRIEF-Translate Bio Announces Results From Second Interim Data Analysis From Ongoing Phase 1/2 Clinical Trial Of MRT5005 In Patients With Cystic Fibrosis

- Translate Bio Inc TBIO.O:

  • TRANSLATE BIO ANNOUNCES RESULTS FROM SECOND INTERIM DATA ANALYSIS FROM ONGOING PHASE 1/2 CLINICAL TRIAL OF MRT5005 IN PATIENTS WITH CYSTIC FIBROSIS (CF)

  • TRANSLATE BIO INC - FIRST INHALED MRNA THERAPEUTIC DELIVERED IN MULTIPLE DOSES TO LUNGS OF CF PATIENTS IS GENERALLY SAFE AND WELL TOLERATED

  • TRANSLATE BIO INC - NO OBSERVED PATTERN OF INCREASES IN PPFEV

  • TRANSLATE BIO INC - PHASE 1/2 CLINICAL TRIAL FOR MRT5005 ONGOING AND NEXT-GENERATION CF CANDIDATE ANTICIPATED TO ENTER IND-ENABLING STUDIES IN 2H 2021

Source text for Eikon: ID:nGNX8XLMTF

Further company coverage: TBIO.O


((Reuters.Briefs@thomsonreuters.com;))